What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis.

RMD Open · 2023 · PMC10152050 · PMID 37116986

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

borderline significantp=0.05actually significant

Outcome percentage SDAI/CDAI/Boolean remission Targeting SDAI/CDAI-LDA significantly improved the percentage of patients in SDAI/CDAI/Boolean remission compared with both DAS-LDA and DAS-remission targets, after 1 year (borderline significant for DAS-LDA) and 2–3 years (year 1: 34% p=0.05 and 35% p=0.03 for comparison to DAS-LDA and DAS-remission respectively, year 2–3: 31% p=0.0002 and 36% p<0.0001) (see figure 2D and online supplemental tables S2 and S3 ).

also in 6,822 other papers

a negative trendno p-value reported

We unexpectedly even found a negative trend on the SHS-score when targeting DAS-remission compared with DAS-LDA, which could potentially be due to residual confounding.

also in 2,510 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.